E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Active immunization against tetanus, diphtheria and pertussis |
|
E.1.1.1 | Medical condition in easily understood language |
Protection against tetanus, diphtheria and pertussis |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10054129 |
E.1.2 | Term | Diphtheria immunisation |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10069577 |
E.1.2 | Term | Pertussis immunisation |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10054131 |
E.1.2 | Term | Tetanus immunisation |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1) To compare pertussis antibody responses induced by Adacel in persons 10 to <11 years of age to those induced by Adacel in persons 11 to <12 years of age.
2) To compare the booster responses against pertussis antigens induced by Adacel in persons 10 to <11 years of age to those induced by Adacel in persons 11 to <12 years of age. |
|
E.2.2 | Secondary objectives of the trial |
Immunogenicity
1) To compare seroprotection rates against tetanus and diphtheria induced by Adacel in persons 10 to <11 years of age to those induced by Adacel in persons 11 to <12 years of age.
2) To compare booster responses against tetanus and diphtheria induced by Adacel in persons 10 to <11 years of age to those induced by Adacel in persons 11 to <12 years of age. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Age is > 10 to < 12 years of age at the time of vaccination.
2) Assent form has been signed and dated by the subject, and informed consent has been signed and dated by the parent(s) or another legally acceptable representative (and by an independent witness if required by local regulations).
3) Subject and parent/guardian are able to attend all scheduled visits and to comply with all trial procedures.
4) For a female of childbearing potential, abstinence or use of an effective method of contraception from at least 4 weeks prior to vaccination until at least 4 weeks after vaccination.
5) Documented vaccination history of receiving 5 previous doses of DTaP vaccine (consisting of 3 infant doses in the first year of life, a 4th dose in the 2nd year of life, and a 5th dose at 4 through 6 years of age). |
|
E.4 | Principal exclusion criteria |
1) Any condition which, in the opinion of the Investigator, would pose a health risk to the participant or interfere with the evaluation of the vaccine.
2) Serious, acute, or chronic disease that is unstable or that, in the opinion of the Investigator, might:
• interfere with the ability to participate fully in the study; or
• interfere with evaluation of the vaccine.
3) Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
4) Prior receipt of pertussis, diphtheria, or tetanus containing vaccines within the past 5 years.
5) A personal history of physician-diagnosed or laboratory confirmed pertussis disease within the last 2 years.
6) A previous severe reaction to pertussis, diphtheria or tetanus vaccine including immediate anaphylaxis, encephalopathy within 7 days or seizure within 3 days of receiving the vaccine.
7) Receipt of blood or blood-derived products in the past 3 months, which might interfere with the assessment of the immune response.
8) Suspected or known hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances.
9) Receipt of any vaccine within 30 days of receiving study vaccine, or plans to receive another vaccine before the 2nd visit; except that influenza vaccine may have been received between 30 and 15 days (but no fewer than 15 days) before receiving study vaccine.
10) Participation in another interventional clinical trial in the 30 days preceding enrollment or planning to participate in another interventional clinical trial during the planned period of this study (between Visit 1 and Visit 2).
11) Seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C, as reported by the parent/guardian.
12) Thrombocytopenia, bleeding disorders, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination.
13) Known pregnancy, or a positive urine or serum pregnancy test.
14) Prior personal history of Guillain-Barré syndrome.
15) Identified as employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employees or the Investigator.
Temporary Contraindications:
A prospective subject must not be included in the study until the following condition(s) and/or symptoms are resolved:
• Febrile illness (temperature ≥100.4°F) or moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Immunogenicity
1) Post-vaccination GMTs to PT, FHA, PRN, and FIM.
2) Booster response rates against pertussis antigens based on anti-PT, FHA, PRN and FIM antibody titer rises between pre- and post-vaccination specimens.
For pertussis antigens, a booster response rate is defined as a four-fold increase in pre- to postvaccination titers for subjects with pre-vaccination titers ≤ 93 EU/mL for PT, ≤ 170 EU/mL for FHA, ≤ 115 EU mL for PRN, and ≤ 285 EU/mL for FIM. If the pre-vaccination titers is >93 EU/mL for PT, >170 EU/mL for FHA, >115 EU mL for PRN, or > 285 EU/mL for FIM then a two-fold increase in the antibody titer would be defined as a booster response.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Post-vaccination
Between Pre-to post vaccination |
|
E.5.2 | Secondary end point(s) |
1) Diphtheria and tetanus seroprotection rates based on post-vaccination antibody titers.
2) Booster response rates against tetanus and diphtheria based on antibody titer rises between pre- and post-vaccination specimens. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Post-vaccination
Between Pre-to post vaccination |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial months | 7 |